Changeflow GovPing Pharma & Drug Safety Gene Therapy for Alzheimer's Disease - Brigham ...
Routine Rule Added Final

Gene Therapy for Alzheimer's Disease - Brigham and Women's Hospital EP3976637

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3976637A1, filed by The Brigham and Women's Hospital, Inc. and The General Hospital Corporation, covering a gene therapy approach for treating Alzheimer's disease. The invention, developed by inventors Shen Jie and Kelleher III Raymond J., is classified under C12N 15/86 and related protein classification C07K 14/47. The patent is designated across all EU member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published patent EP3976637A1 for a gene therapy method targeting Alzheimer's disease, with inventors Shen Jie and Kelleher III Raymond J., assigned to The Brigham and Women's Hospital, Inc. and The General Hospital Corporation. The patent covers the therapeutic composition and method of use classified under C12N 15/86.

Affected parties in the biotechnology and pharmaceutical sectors should monitor this patent landscape for freedom-to-operate considerations, as the granted claims may restrict development of competing gene therapy approaches for Alzheimer's disease within EU member states.

What to do next

  1. Monitor patent register for potential infringement implications
  2. Review licensing opportunities for gene therapy technology

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

GENE THERAPY FOR ALZHEIMER'S DISEASE

Publication EP3976637A1 Kind: A1 Apr 08, 2026

Applicants

The Brigham and Women's Hospital, Inc., The General Hospital Corporation

Inventors

SHEN, Jie, KELLEHER III, Raymond J.

IPC Classifications

C07K 14/47 20060101AFI20230515BHEP C12N 15/67 20060101ALI20230515BHEP C12N 15/86 20060101ALI20230515BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3976637A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Investors
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Gene therapy Biotechnology research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!